MAYOLY SPINDLER Committed to your health. Every day. 19-INS-319 - - PowerPoint PPT Presentation

MAYOLY SPINDLER Committed to your health. Every day.

19-INS-319

2

OUR AMBITION

Become an international reference in gastroenterology and dermo-cosmetics

CONTENTS

OUR ASSETS

A French company An independent company An extensive global footprint

08/07/2019 CORPORATE PRESENTATION 3

OUR EMPLOYEES’ COMMITMENT

Our values A responsible company

OUR FIELDS OF EXPERTISE

Pharmaceuticals Diagnostic Dermo-cosmetics Contract Development & Manufacturing

OUR ASSETS a French company

▪ Three manufacturing facilities near Paris, 1 in Chatou (West of Paris) and 2 in Dammarie-les-Lys (East of Paris). ▪ Over 900 employees worldwide, including nearly 600 in France. ▪ Turnover: €182 million in 2018. ▪ 70% of products sold are made in France. ▪ An economic player contributing to France’s status as

• ne of the world’s leading pharmaceuticals exporters*.

▪ Exported production : €51 million

4 08/07/2019 CORPORATE PRESENTATION

* Source: LEEM (French Pharmaceutical Companies Association)– Economic report, 2016 issue.

OUR ASSETS an independent company

▪ Founded in 1909: for more than a century, an entrepreneurial adventure. ▪ Still an entirely family-owned company. ▪ Financial independence, a main performance driver.

5 08/07/2019 CORPORATE PRESENTATION

126 138 145 154 159 161 167 173 190 182

20 40 60 80 100 120 140 160 180 200 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018

NET CONSOLIDATED TURNOVER 2009-2018 (€ million)

OUR ASSETS an extensive global footprint

▪ Established worldwide in more than 70 countries generating 41% of overall turnover

▪ Dynamic subsidiaries: in Europe, Eastern Europe, Asia and Latin America (26% of international turnover in 2018) ▪ Business partners committed for the long term

▪ A proactive development policy

▪ With the acquisition in 2016 of Kibion, a Swedish company principally operating in Germany and the Middle East, Mayoly Spindler has become one of the world leaders in the detection and control of Helicobacter pylori infections.

08/07/2019 CORPORATE PRESENTATION 6

Subsidiaries Distributors

OUR FIELDS OF EXPERTISE

7

PHARMACEUTICALS

8

PHARMACEUTICALS

Our historical pillar of development

▪ Pharmaceutical sector: 72% of overall turnover in 2018 ▪ Gastroenterology: 80% of our pharmaceutical business. ▪ A portfolio of therapeutic solutions spanning speciality care, primary care and self-medication. ▪ An investment in collaborative R&D in gastroenterology.

08/07/2019 CORPORATE PRESENTATION 9

BREAKDOWN OF TURNOVER BY BUSINESS SECTOR IN 2018

* Contract Development & Manufacturing Organization

Pharmaceuticals 131 million € Dermo-cosmetics 26 million € Diagnostic 13 million € CDMO* 12 million €

13 % 7 %

72 %

7 %

08/07/2019 CORPORATE PRESENTATION 10

OUR THERAPEUTIC SOLUTIONS PORTFOLIO IN GASTROENTEROLOGY

10

Travel sickness Digestive and renal elimination functions Probiotics/Gut flora Constipation Colonoscopy Acid reflux Heartburn Biliary lithiasis Biliary cirrhosis Pancreatic insufficiency Cystic fibrosis Crohn’s disease Helicobacter pylori Abdominal pains Gaz

Rx OTC

L’ACTIVITE DIAGNOSTIC

08/07/2019 PRÉSENTATION À DESTINATION EXCLUSIVE DES INSTITUTIONNELS 11

DIAGNOSTIC

DIAGNOSTIC

Our strategic pillar of development

▪ In 2016, Mayoly Spindler acquired Kibion, the world leader in fast and reliable urea breath testing machines and tests for the diagnosis and eradication control of Helicobacter pylori. ▪ In 2019, Mayoly Spindler creates Mayoly Diagnostic, the business unit dedicated to the devlopment of the Helicobacter pylori infection diagnosis business.

08/07/2019 CORPORATE PRESENTATION

BREAKDOWN OF TURNOVER BY BUSINESS SECTOR IN 2018

12 08/07/2019

* Contract Development & Manufacturing Organization

Pharmaceuticals 131 million € Dermo-cosmetics 26 million € Diagnostic 13 million € CDMO* 12 million €

13 % 7 %

72 %

7 %

DIAGNOSTIC

Our strategic pillar of development

▪ 95% of duodenal ulcers and 70% of gastric ulcers are attributable to Helicobacter pylori’s infection. ▪ Nearly 4 billion people worldwide are infected.

08/07/2019 CORPORATE PRESENTATION 13 08/07/2019

DERMO-COSMETICS

14

DERMOCOSMETICS

Topicrem, the science of hydration

▪ Topicrem: n°1 in body moisturizing milks in pharmacies in France since 2013*. ▪ High-quality manufacturing standards recognized

• n an international level.

▪ All worldwide production of Topicrem is made in France (Dammarie-Les-Lys). ▪ An international brand (50% of Topicrem sales generated outside of France).

08/07/2019 CORPORATE PRESENTATION 15

BREAKDOWN OF TURNOVER BY BUSINESS SECTOR IN 2018

* Contract Development & Manufacturing Organization

* Source : IQVIA — Pharmatrend PharmaOne (2016-2018) Pharmatrend NMNM (2013-2016)— marché des hydratants émollients corps femme en lait/lotion — 2013 a 2018 — en volume.

Pharmaceuticals 131 million € Dermo-cosmetics 26 million € Diagnostic 13 million € CDMO* 12 million €

13 % 7 %

72 %

7 %

PRODUCTION & CONTRACT MANUFACTURING

16

PRODUCTION & CONTRACT MANUFACTURING Technical prowess and responsiveness

▪ Three manufacturing facilities near Paris, 1 in Chatou (West of Paris) and 2 in Dammarie-les-Lys (East

• f Paris).

▪ A softgel capsules expertise requiring a particular technicality. ▪ A light and reactive structure that adapts to the requirements of our customers.

08/07/2019 CORPORATE PRESENTATION 17

BREAKDOWN OF TURNOVER BY BUSINESS SECTOR IN 2018

* Contract Development & Manufacturing Organization

Pharmaceuticals 131 million € Dermo-cosmetics 26 million € Diagnostic 13 million € CDMO* 12 million €

13 % 7 %

72 %

7 %

PRODUCTION & CONTRACT MANUFACTURING Technical prowess and responsiveness

08/07/2019 CORPORATE PRESENTATION 18

▪ A diversified offer: pharmaceuticals, nutraceuticals, dermocosmetics ▪ Various galenic forms: soft capsules, tablets, capsules, suppositories, oils, emulsions, gel, micellar solutions…

OUR EMPLOYEES’ COMMITMENT, CENTRAL TO OUR SUCCESS

19

OUR VALUES

08/07/2019 CORPORATE PRESENTATION 20

Our performance is the result of the talent of our employees who, every day, share ambitious projects and a test for challenge. Our corporate culture is reflected in the empowerment of our teams, the opportunity to take initiatives and the pragmatism of each individual. Mayoly Spindler is a company where respect goes hand-in-hand with growth, fostering the well-being of everyone.

RESPONSIBILITY RESPECT PRAGMATISM

A RESPONSIBLE COMPANY

▪ OUR MAYOLY, our corporate responsibility programme. ▪ Three priorities: workplace well-being, commitment to the community and care for the environment. ▪ Projects designed and coordinated by employees, working in the general interest.

08/07/2019 CORPORATE PRESENTATION 21

MAYOLY SPINDLER AT A GLANCE

22

41%

• f turnover generated
• utside of France.

23

3 production sites

near Paris: 1 in Chatou and 2 in Dammarie-les-lys

€182 million turnover

Pharmaceuticals: 72% Diagnostic : 7% Dermo-cosmetics: 13% Production: 7%

Over 900

employees worldwide, including 600 in France.

Figures as at 12/31/2018.

Committed to your health. Every day.